SuperworthCerus profit margin CERS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −2.9%
- Operating margin, 12 months
- −0.7%
- Net margin on a year earlier
- +6.4 pts
- Peer median
- 7.8%
Over the twelve months to Jun 30, 2026, Cerus kept −2.9% of its revenue as net profit, with an operating margin of −0.7% and a gross margin of 48.9%.
Five years earlier its net margin was −47.1%.
The median for 10 medical instruments and supplies stocks of a similar size is 7.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −7.1% | −3.9% | 50.9% |
| FY2024 | −10.4% | −7.1% | 49.4% |
| FY2023 | −20.1% | −16.1% | 46.3% |
| FY2022 | −22.7% | −18.1% | 46.2% |
| FY2021 | −34.1% | −30.7% | 42.2% |
| FY2020 | −52.4% | −51.1% | 44.4% |
| FY2019 | −76.0% | −70.6% | 44.0% |
| FY2018 | −75.7% | −72.3% | 38.5% |
| FY2017 | n/a | n/a | 48.3% |
| FY2016 | n/a | n/a | 45.4% |
| FY2015 | n/a | n/a | 31.4% |
| FY2014 | n/a | n/a | 41.8% |
| FY2013 | n/a | −71.4% | 43.0% |
| FY2012 | −43.4% | −47.1% | 43.8% |
| FY2011 | −55.5% | −52.0% | 39.4% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −2.9% | +6.4 pts | −0.7% | |
| Q1 FY26 | −4.1% | +5.3 pts | −1.4% | |
| Q4 FY25 | −7.1% | +3.3 pts | −3.9% | |
| Q3 FY25 | −7.5% | +2.5 pts | −4.5% | |
| Q2 FY25 | −9.3% | +3.1 pts | −5.8% | |
| Q1 FY25 | −9.4% | +7.0 pts | −6.0% | |
| Q4 FY24 | −10.4% | +9.7 pts | −7.1% | |
| Q3 FY24 | −10.0% | +17.0 pts | −6.0% | |
| Q2 FY24 | −12.4% | +15.4 pts | −8.3% | |
| Q1 FY24 | −16.5% | +8.6 pts | −12.5% | |
| Q4 FY23 | −20.1% | +2.6 pts | −16.1% | |
| Q3 FY23 | −26.9% | −6.5 pts | −22.2% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Cerus' size, closest first, today.
| Company | Profit margin |
|---|---|
| CERSCerus | −2.9% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| EMBCEmbecta | 8.6% |
| MOVMovado | 6.0% |
| INFUInfuSystem | 6.0% |
| UTMDUtah Medical Products | 29.0% |
| IRMDIradimed | 26.7% |
| PDEXPro DEX | 17.6% |
| STAAStaar Surgical | 1.1% |
| BVSBioventus | 9.4% |
| Peer median | 7.8% |
Where Cerus ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Cerus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.